Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features

Thrombotic thrombocytopenic purpura (TTP) is an acute, rare, life‐threatening disorder. This report presents the South East (SE) England registry for TTP, from April 2002 to December 2006, which included 176 patients and 236 acute episodes; 75% of patients were female and 25% were male, overall median age at presentation was 42 years. Mortality was 8·5%, most cases died before treatment was instigated. The main ethnic groups were Caucasian (64%) and Afro Caribbean (27%). Seventy‐seven percent of cases were idiopathic, 5% were congenital and the remaining cases had a defined precipitant. Neurological features were the most prevalent, but cardiac involvement accounted for 42% of presenting features. The overall median number of plasma exchanges (PEXs) to remission was 15; between April 2002 and December 2003, the median number of PEXs was 19 and it was 12 between January 2004 and December 2006 (P < 0·0001). In the latter period, adjuvant therapies were reduced, but Rituximab was increased. ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity was <10% in 74% and 95% of these cases had positive IgG antibodies to ADAMTS 13. Renal impairment and delayed normalisation of platelet count were the main differences between idiopathic and secondary TTP.

[1]  R. Oster,et al.  Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: a single‐institution experience , 2007, Transfusion.

[2]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[3]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[4]  L. Corash,et al.  Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S‐59) and ultraviolet A light , 2005, Transfusion.

[5]  J. Mira,et al.  Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpura , 2006, British journal of haematology.

[6]  B. Lämmle,et al.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. , 2005, Blood.

[7]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[8]  R. Miller,et al.  Thrombotic thrombocytopaenic purpura in HIV-infected patients , 2005, International journal of STD & AIDS.

[9]  M. Minegishi,et al.  Deficient Activity of von Willebrand Factor-Cleaving Protease in Patients With Upshaw-Schulman Syndrome , 2001, International journal of hematology.

[10]  B. Lämmle,et al.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. , 1997, Blood.

[11]  B. Lämmle,et al.  Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF , 1999, Thrombosis and Haemostasis.

[12]  B. Lämmle,et al.  Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. , 1998, Blood.

[13]  B. Hunt,et al.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias , 2003, British journal of haematology.

[14]  H. Tsai.  High titers of inhibitors of von Willebrand factor‐cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura , 2000, American journal of hematology.

[15]  B. Lämmle,et al.  Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. , 2004, Blood.

[16]  F. Dorner,et al.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. , 2003, Blood.

[17]  W. Miesbach,et al.  The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine , 2005, British journal of haematology.

[18]  A. Garg,et al.  Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange , 2006, British journal of haematology.

[19]  S. Vesely,et al.  The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency , 2005, Journal of thrombosis and haemostasis : JTH.

[20]  S. Vesely,et al.  Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome , 2004, Transfusion.

[21]  A. Eldor,et al.  High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. , 1987, The American journal of medicine.

[22]  B. Lämmle,et al.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.

[23]  G. Rock,et al.  Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura , 1995, Annals of Internal Medicine.

[24]  G. Remuzzi,et al.  Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. , 2005, Blood.

[25]  P. Mannucci,et al.  von Willebrand factor cleaving protease (ADAMTS‐13) and ADAMTS‐13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura , 2004, British journal of haematology.

[26]  M. Scully,et al.  The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura , 2007, British journal of haematology.

[27]  K. Lassoued,et al.  Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement , 2004, Medicine.

[28]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[29]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[30]  B. Lämmle,et al.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. , 1996, Blood.

[31]  Miha Furlan,et al.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.

[32]  D. Cines,et al.  Thrombotic microangiopathy during pregnancy. , 1997, Seminars in hematology.

[33]  E. Moschcowitz.  Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease , 1924 .

[34]  R. Liesner,et al.  von Willebrand factor‐cleaving protease activity in congenital thrombotic thrombocytopenic purpura , 2000, British journal of haematology.

[35]  A. Houllier,et al.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. , 2001, Blood.

[36]  J. Kelton,et al.  Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. , 2001, Blood.

[37]  J. Cavenagh,et al.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13 , 2007, British journal of haematology.

[38]  M. Brecher,et al.  United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange , 1998, Journal of clinical apheresis.